Skip to main content
letter
. 2016 Aug;101(8):e332–e335. doi: 10.3324/haematol.2015.139568

Figure 2.

Figure 2.

Course of initial disease and relapse. (A) Initial disease: course of leukemic blasts detected in bone marrow (%) and minimal residual disease (MRD) load (immunoglobulin heavy chain locus; QR: 1E-04) under treatment according to the ALL-BFM-2000 study protocol [Prot. IA-P+ and IB (I); Prot. M (M); Prot. II (II); maintenance therapy]; maintenance therapy was continued until April 2003 [BM: complete remission (CR)]. (B) Relapse: course of leukemic blasts detected in bone marrow (%) and minimal residual disease (MRD) load (immunoglobulin heavy chain locus; QR: 1E-04) under treatment according to the ALL-REZ-BFM-2002 study protocol – S2A [Prot. F1 and F2 (F); Prot. II-IDA (II-IDA); Prot. R1 and R2 (R); CNS irradiation (↓); maintenance therapy (D24/V)]; maintenance therapy was continued until March 2007; imatinib treatment was continued until November 2012. Further bone marrow assessment: complete remission in April 2006, 2007 and 2008, MRD not detectable in April 2008.